Navigation Links
Intelliject, Inc. Enters Into Licensing Agreement with sanofi-aventis for U.S./Canada Rights to Novel Epinephrine Auto-injector
Date:11/30/2009

RICHMOND, Va., Nov. 30 /PRNewswire/ -- Intelliject, Inc. today announced an exclusive license with sanofi-aventis U.S. for a novel epinephrine auto-injector, in the U.S. and Canada territory. Under the license, sanofi-aventis U.S. shall be responsible for manufacturing and commercialization. Intelliject will be responsible for the on-going development and for obtaining U.S. regulatory approval and has retained certain co-promotion rights in the territory.

Sanofi-aventis U.S. will pay an initial upfront payment of $25 million. Intelliject will also be eligible to receive development and commercial milestones of up to $205 million as well as tiered double-digit royalties on sales of any products commercialized under the license.

"We are delighted to have sanofi-aventis U.S. as our partner with their proven track record in and commitment to the allergy/immunology area. This partnership marks a key milestone in our quest to make our novel epinephrine auto-injector available to the millions of patients at risk for anaphylaxis. We expect it to create significant long-term value for the company; it marks the first step on our mission to bring the same innovation and patient-centric solutions to many different therapy areas. Intelliject's unique model -- drug development expertise combined with a proprietary, patient-centric delivery platform -- has the potential to dramatically redefine the "Standard of Care" in multiple biopharmaceutical categories," said Spencer Williamson, President and CEO of Intelliject.

About anaphylaxis

Anaphylaxis is a severe allergic reaction that involves a number of body systems and can be fatal within minutes. The American College of Allergy, Asthma and Immunology estimates there are up to 2,000 episodes of anaphylaxis per every 100,000 people in the U.S. each year, although the precise incidence of anaphylaxis is unknown and is likely underreported.

Anaphylaxis can occur in people with allergies to certain foods, insect stings, medications, latex or other allergens. All published national anaphylaxis guidelines recommend epinephrine as the first choice treatment in an acute episode. The vast majority of deaths from anaphylaxis occur in individuals who do not receive epinephrine in a timely manner.

About Intelliject

Intelliject is a specialty pharmaceutical company dedicated to developing combination drug/device products that empower patients to control and gain freedom from their medical conditions. Each Intelliject product in development combines an established drug, an innovative delivery platform and a supporting dossier intended to show superiority, patient preference and cost effectiveness data.

Intelliject applies rigorous selection criteria to identify areas where its patient-centric approach and proprietary technology will offer superior solutions. The company only proceeds to an active development program once it has established that incremental clinical and economic benefit is achievable. Intelliject has a focused pipeline of active programs across a number of therapeutic areas, including small molecules and biologics.

Intelliject is a privately-held company headquartered in Richmond, Virginia. For online information please visit www.intelliject.com.

Intelliject Disclaimer

This press release contains forward-looking statements, including statements regarding the expected benefits of Intelliject's collaboration agreement with sanofi-aventis U.S. Statements that are not historical facts are based on Intelliject's current expectations, beliefs, assumptions, estimates, forecasts and projections about the industry and markets in which Intelliject competes. The statements contained in this release are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements. Important factors which may affect the expected benefits of Intelliject's collaboration and license agreements with sanofi-aventis U.S. include, but are not limited to, the risks that its novel epinephrine auto-injector may not gain market acceptance; Intelliject may not be able to obtain and maintain intellectual property protection for its products and technologies; and Intelliject may not obtain necessary regulatory approval. Intelliject cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this release, and Intelliject undertakes no obligations to update or revise these statements, except as may be required by law. Intelliject specifically disclaims responsibility for information describing sanofi-aventis U.S. and its business other than the license with Intelliject.


Media Contact:
Jenn Riggle
757/640-1982  ext. 25
757/615-6099 (cell)
jriggle@crt-tanaka.com

SOURCE Intelliject, Inc.


'/>"/>
SOURCE Intelliject, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Sanofi-aventis U.S. and Intelliject, Inc. Sign Licensing Agreement for Novel Epinephrine Auto Injector in North America
2. FUJIFILM Enters Advanced Visualization Market
3. Covance Enters Into a Biomarker Alliance With Rules-Based Medicine, Inc.
4. Arigene Co., Ltd. Enters Into Amendment To Merger Agreement With Trimeris, Inc.
5. Sigma-Aldrich Enters Distribution Agreement With Stemgent, Inc. to Offer Lentivirus-Based Gene Delivery Products for Regenerative Medicine and Stem Cell Research
6. Prasco Enters into Agreements with sanofi-aventis U.S. to Provide Sales Support and Distribution Services for Authorized Generic Versions Under the Winthrop Label in U.S.
7. Accurays Treatment Planning Service Active at 20 Percent of U.S. CyberKnife Centers
8. Biomoda Enters Final Stage of Patient Testing for Phase II Lung Cancer Clinical Study
9. Potentia Pharmaceuticals Enters into Licensing and Purchase Option Agreements with Alcon
10. Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia
11. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... Biosimilar Clinical Trial & Opportunity Insight" report by PNS Pharma gives comprehensive ... Currently 5 biosimilar version of Lantus are commercially available in ... , Czech Republic , Estonia , ... Slovakia , United Kingdom for the treatment ... in 2014. Lantus is the brand name for Insulin Glargine, a ...
(Date:12/7/2016)... Global Cervical Dysplasia Market: Scope and ... dysplasia market analyzes the current and future prospects ... executive summary, including a market snapshot that provides ... The research is a combination of primary and ... our research efforts along with information collected from ...
(Date:12/7/2016)... -- A new investigational drug originally developed for type 2 ... of the world,s first treatment to impede the progression of ... in the journal Science Translational Medicine . ... for millions of people living with Parkinson,s disease," says ... Research Institute,s Center for Neurodegenerative Science , chairman ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... Levels of a protein in the blood ... study appearing online in the journal Radiology. , Heart disease and brain disease exact ... to the rapidly aging population. Damage to both organs often occurs at a subclinical ...
(Date:12/7/2016)... ... December 07, 2016 , ... ODU, ... to the US market its advanced highly customizable contact technology solutions. , ODU ... These advanced technologies are ideal for a wide range of applications that require ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... planning services to families and business owners in the greater Dallas metropolitan area, ... the Dallas Fallen Officer Foundation. , Established in 2009 by active police professionals ...
(Date:12/7/2016)... ... 2016 , ... A. Kevin Spann Insurance, a New York-based firm offering insurance ... launching a charity drive to raise funds that will benefit the Marine Corps League. ... and Navy FMF Corpsmen. Working closely with the MCL, the A. Kevin Spann team ...
(Date:12/7/2016)... Honolulu, HI (PRWEB) , ... December 07, 2016 ... ... Dermatology is proud to announce that its fully redesigned website, which launched October ... well as a sleek responsive design and easy-to-navigate layout. Visitors and patients can ...
Breaking Medicine News(10 mins):